Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  215 results for ""NATALIZUMAB""

Your Filters

Publisher : wiley
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Brain Atrophy in Natalizumab-treated Patients with Multiple Sclerosis: A 5-year Retrospective Study.

  • Authors : Eisele P; Department of Neurology, Universitätsmedizin Mannheim, University of Heidelberg, Mannheim, Baden-Württemberg, Germany.; Szabo K

Subjects: Atrophy/Atrophy/Atrophy/*chemically induced ; Brain/Brain/Brain/*pathology ; Immunologic Factors/Immunologic Factors/Immunologic Factors/*adverse effects

  • Source: Journal of neuroimaging : official journal of the American Society of Neuroimaging [J Neuroimaging] 2019 Mar; Vol. 29 (2), pp. 190-192. Date of Electronic Publication: 2018 Nov 28.Publisher: Wiley Country of Publication: United States NLM ID: 9102705 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every-4-Week Dosing to Extended-Interval Dosing.

Subjects: Models, Biological*; Immunologic Factors/Immunologic Factors/Immunologic Factors/*administration & dosage ; Multiple Sclerosis/Multiple Sclerosis/Multiple Sclerosis/*drug therapy

  • Source: Journal of clinical pharmacology [J Clin Pharmacol] 2021 Mar; Vol. 61 (3), pp. 339-348. Date of Electronic Publication: 2020 Sep 19.Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Natalizumab for induction of remission in Crohn's disease.

  • Authors : Nelson SM; Department of Medicine, University of Western Ontario, London, Canada.; Nguyen TM

Subjects: Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*therapeutic use ; Crohn Disease/Crohn Disease/Crohn Disease/*drug therapy ; Immunologic Factors/Immunologic Factors/Immunologic Factors/*therapeutic use

  • Source: The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2018 Aug 01; Vol. 8. Cochrane AN: CD006097. Date of Electronic Publication: 2018 Aug 01.Publisher: Wiley Country of Publication: England NLM ID: 100909747 Publication Model: Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis.

  • Authors : Boremalm M; Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå.; Juto A

Subjects: Fingolimod Hydrochloride/Fingolimod Hydrochloride/Fingolimod Hydrochloride/*therapeutic use ; Immunologic Factors/Immunologic Factors/Immunologic Factors/*therapeutic use ; Multiple Sclerosis, Relapsing-Remitting/Multiple Sclerosis, Relapsing-Remitting/Multiple Sclerosis, Relapsing-Remitting/*drug therapy

  • Source: European journal of neurology [Eur J Neurol] 2019 Aug; Vol. 26 (8), pp. 1060-1067. Date of Electronic Publication: 2019 Mar 12.Publisher: Wiley Country of Publication: England NLM ID: 9506311 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Safety and efficacy of autologous hematopoietic stem-cell transplantation following natalizumab discontinuation in aggressive multiple sclerosis.

  • Authors : Mariottini A; Department of Neurosciences Drug and Child Health, University of Florence, Florence.; Department of Neurology 2 and Multiple Sclerosis Regional Referral Centre, Careggi University Hospital, Florence.

Subjects: Hematopoietic Stem Cell Transplantation/Hematopoietic Stem Cell Transplantation/Hematopoietic Stem Cell Transplantation/*adverse effects ; Immunosuppressive Agents/Immunosuppressive Agents/Immunosuppressive Agents/*therapeutic use ; Multiple Sclerosis, Relapsing-Remitting/Multiple Sclerosis, Relapsing-Remitting/Multiple Sclerosis, Relapsing-Remitting/*therapy

  • Source: European journal of neurology [Eur J Neurol] 2019 Apr; Vol. 26 (4), pp. 624-630. Date of Electronic Publication: 2018 Dec 14.Publisher: Wiley Country of Publication: England NLM ID: 9506311 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients.

  • Authors : van Kempen ZLE; Department of Neurology, Amsterdam Neuroscience, VUmc MS Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.; Leurs CE

Subjects: JC Virus*; Immunologic Factors/Immunologic Factors/Immunologic Factors/*adverse effects ; Leukoencephalopathy, Progressive Multifocal/Leukoencephalopathy, Progressive Multifocal/Leukoencephalopathy, Progressive Multifocal/*complications

  • Source: European journal of neurology [Eur J Neurol] 2017 Sep; Vol. 24 (9), pp. 1196-1199. Date of Electronic Publication: 2017 Jul 14.Publisher: Wiley Country of Publication: England NLM ID: 9506311 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis.

Subjects: Models, Biological*; Multiple Sclerosis/Multiple Sclerosis/Multiple Sclerosis/*metabolism ; Natalizumab/Natalizumab/Natalizumab/*pharmacokinetics

  • Source: Journal of clinical pharmacology [J Clin Pharmacol] 2017 Aug; Vol. 57 (8), pp. 1017-1030. Date of Electronic Publication: 2017 Apr 11.Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis.

Subjects: Multiple Sclerosis/Multiple Sclerosis/Multiple Sclerosis/*drug therapy ; Natalizumab/Natalizumab/Natalizumab/*administration & dosage ; Natalizumab/Natalizumab/Natalizumab/*therapeutic use

  • Source: Journal of clinical pharmacology [J Clin Pharmacol] 2016 Oct; Vol. 56 (10), pp. 1254-62. Date of Electronic Publication: 2016 Mar 03.Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

High cumulative JC virus seroconversion rate during long-term use of natalizumab.

  • Authors : Vennegoor A; Department of Neurology, MS Centre Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands.; van Rossum JA

Subjects: Antibodies, Viral/Antibodies, Viral/Antibodies, Viral/*blood ; Immunologic Factors/Immunologic Factors/Immunologic Factors/*adverse effects ; JC Virus/JC Virus/JC Virus/*immunology

  • Source: European journal of neurology [Eur J Neurol] 2016 Jun; Vol. 23 (6), pp. 1079-85. Date of Electronic Publication: 2016 Mar 27.Publisher: Wiley Country of Publication: England NLM ID: 9506311 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.

  • Authors : Domínguez-Mozo MI; Department of Neurology, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Hospital Clínico San Carlos, Madrid, Spain.; García-Montojo M

Subjects: JC Virus*; DNA, Viral/DNA, Viral/DNA, Viral/*blood ; Immunologic Factors/Immunologic Factors/Immunologic Factors/*therapeutic use

  • Source: European journal of neurology [Eur J Neurol] 2016 Jan; Vol. 23 (1), pp. 182-9. Date of Electronic Publication: 2015 Oct 25.Publisher: Wiley Country of Publication: England NLM ID: 9506311 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
  • 1-10 of  215 results for ""NATALIZUMAB""